Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection

This study has been completed.
Baylor College of Medicine
Information provided by:
VA Medical Center, Houston Identifier:
First received: March 16, 2006
Last updated: September 25, 2009
Last verified: September 2009

The purpose of this study is to compare the outcome of treatment for bacteremic MRSA infection with vancomycin alone, vancomycin plus gentamicin, vancomycin plus rifampin, and vancomycin plus gentamicin and rifampin.

Condition Intervention Phase
Staphylococcus Aureus
Drug: Vancomycin
Drug: Vancomycin plus Gentamicin
Drug: Vancomycin plus Rifampin
Drug: Vancomycin plus Gentamicin plus Rifampin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Official Title: Vancomycin Versus Vancomycin Plus Gentamycin For Treating Bacteremic Infection Due to Methicillin-Resistant Staphylococcus Aureus (MRSA)

Resource links provided by NLM:

Further study details as provided by VA Medical Center, Houston:

Primary Outcome Measures:
  • Time to defervescence (24 hours of temperature <100 degrees F)
  • Return of WBC to normal (<10,500)
  • negative blood cultures
  • discharge

Estimated Enrollment: 160
Study Start Date: January 2006
Study Completion Date: January 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with MRSA in a blood culture processed as standard of care at the VAMC
  • Patients or next of kin willing to sign consent to be randomized by social security number to one of the treatments.

Exclusion Criteria:

  • none
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00304811

United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Michael E. DeBakey Veterans Affairs Medical Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
VA Medical Center, Houston
Baylor College of Medicine
Principal Investigator: Daniel M Musher, MD Baylor College of Medicine, Houston VA Medical Center
  More Information

No publications provided Identifier: NCT00304811     History of Changes
Other Study ID Numbers: H-17556
Study First Received: March 16, 2006
Last Updated: September 25, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by VA Medical Center, Houston:
Methicillin Resistant Staphylococcus aureus

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antitubercular
Antitubercular Agents
Enzyme Inhibitors
Leprostatic Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Protein Synthesis Inhibitors
Therapeutic Uses processed this record on February 27, 2015